<p>全球阿尔法资本管理有限公司在最近提交给证券交易委员会的 13F 表格中披露，在第一季度将其在海默尼克斯公司的股份（纽约证券交易所代码：HAE - 免费报告）增加了 61.1%。该公司在此期间额外购买了 10,452 股后，持有 27,553 股医疗仪器供应商的股票。全球阿尔法资本管理有限公司在最近一个季度末持有海默尼克斯约 0.05% 的股份，价值 1,751,000 美元。</p>
<p>其他机构投资者和对冲基金最近也增加或减少了在该公司的持股。路易斯安那州员工退休系统在第一季度将其在海默尼克斯的股份增加了 1.4%。路易斯安那州员工退休系统现在持有 14,100 股医疗仪器供应商的股票，价值 896,000 美元，此前在此期间额外购买了 200 股。CWC Advisors LLC 在第四季度将其在海默尼克斯的股份增加了 7.4%。CWC Advisors LLC 现在持有 3,083 股医疗仪器供应商的股票，价值 241,000 美元，此前在此期间额外购买了 212 股。Vise Technologies Inc.在第四季度将其在海默尼克斯的股份增加了 8.7%。Vise Technologies Inc.现在持有 2,825 股医疗仪器供应商的股票，价值 221,000 美元，此前在此期间额外购买了 225 股。TD Waterhouse Canada Inc.在第四季度购买了海默尼克斯的新股份，价值约 25,000 美元。最后，KBC Group NV 在第一季度将其在海默尼克斯的股份增加了 19.9%。KBC Group NV 现在持有 2,417 股医疗仪器供应商的股票，价值 154,000 美元，此前在此期间额外购买了 401 股。目前 99.67% 的股票由机构投资者持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>几家研究公司最近对 HAE 发表了看法。摩根大通重申了对海默尼克斯的 “中性” 评级，并在周五的研究报告中将目标价下调至 62.00 美元（之前为 85.00 美元）。JMP 证券在 5 月 20 日的研究报告中重申了对海默尼克斯的 “市场表现优于大盘” 评级，并将目标价设定为 100.00 美元。Wall Street Zen 在 5 月 13 日的研究报告中将海默尼克斯的评级从 “买入” 下调至 “持有”。Needham &amp; Company LLC 在周四将海默尼克斯的目标价从 84.00 美元下调至 68.00 美元，并对该股票设定了 “买入” 评级。最后，瑞穗证券在周五将海默尼克斯的目标价从 90.00 美元下调至 70.00 美元，并对该股票设定了 “优于大盘” 评级。一位股票研究分析师对该股票给予了卖出评级，两位给予了持有评级，八位给予了买入评级，两位给予了强烈买入评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，共识目标价为 87.64 美元。</p>
<p><strong>查看我们关于海默尼克斯的最新报告</strong></p>
<h2>海默尼克斯价格表现</h2>
<p>海默尼克斯的股票在周五开盘价为 53.88 美元。该公司的债务与股本比率为 1.04，速动比率为 0.99，流动比率为 1.72。该公司的市值为 25.9 亿美元，市盈率为 16.48，市盈增长比率为 0.90，贝塔值为 0.40。该公司的 50 日移动平均线为 72.88 美元，200 日移动平均线为 67.44 美元。海默尼克斯公司的 52 周低点为 53.25 美元，52 周高点为 94.99 美元。</p>
<p>海默尼克斯（纽约证券交易所代码：HAE - 获取免费报告）最近在 8 月 7 日发布了季度财报。该医疗仪器供应商报告季度每股收益为 1.10 美元，超出分析师一致预期的 1.01 美元，超出幅度为 0.09 美元。该公司季度收入为 3.2139 亿美元，而分析师预期为 3.0512 亿美元。海默尼克斯的股本回报率为 26.64%，净利润率为 12.14%。该公司的收入同比下降了 4.4%。在去年同期，该公司每股收益为 1.02 美元。股票研究分析师预测海默尼克斯公司本财年的每股收益将达到 4.55 美元。</p>
<h2>海默尼克斯简介</h2>
<p>（免费报告）</p>
<p>海默尼克斯公司是一家医疗保健公司，在美国和国际上提供一系列医疗产品和解决方案。该公司提供自动化血浆采集系统、捐赠者管理软件及支持软件解决方案，包括 NexSys PCS 和 PCS2 血浆分离设备及相关耗材和解决方案，以及集成的信息技术平台，供血浆客户管理其捐赠者、运营和供应链；以及 NexLynk DMS 捐赠者管理系统和 Donor360 应用程序。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好五只股票，而不是海默尼克斯</li>
<li>想在下跌趋势中获利？下跌趋势解析。</li>
<li>MarketBeat 周回顾 – 08/04 - 08/08</li>
<li>股票平均计算器</li>
<li>Airbnb 超出收益预期，但增长故事正在失去高度</li>
<li>股票中的死亡交叉是什么？</li>
<li>Netflix 的多头与空头：谁将在这次回调中获胜？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在海默尼克斯吗？</h2>
<p>在你考虑海默尼克斯之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Haemonetics 并不在名单上。</p>
<p>虽然 Haemonetics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>全球阿尔法资本管理有限公司在第一季度将其在海蒙尼克斯公司（NYSE:HAE）的持股增加了 61.1%，增持了 10,452 股，总持股达到 27,553 股，价值 175 万美元。其他机构投资者也调整了他们的持股。分析师对海蒙尼克斯的评级意见不一，普遍评级为 “适度买入”，目标价为 87.64 美元。该股票开盘价为 53.88 美元，市值为 25.9 亿美元，最近的每股收益为 1.10 美元，超出预期。海蒙尼克斯报告的收入同比下降了 4.4%</p>

<p>Global Alpha Capital Management Ltd. boosted its position in shares of Haemonetics Corporation (NYSE:HAE - Free Report) by 61.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm owned 27,553 shares of the medical instruments supplier's stock after acquiring an additional 10,452 shares during the period. Global Alpha Capital Management Ltd. owned approximately 0.05% of Haemonetics worth $1,751,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>全球阿尔法资本管理有限公司在最近提交给证券交易委员会的 13F 表格中披露，在第一季度将其在海默尼克斯公司的股份（纽约证券交易所代码：HAE - 免费报告）增加了 61.1%。该公司在此期间额外购买了 10,452 股后，持有 27,553 股医疗仪器供应商的股票。全球阿尔法资本管理有限公司在最近一个季度末持有海默尼克斯约 0.05% 的股份，价值 1,751,000 美元。</p>
</div><p>Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Louisiana State Employees Retirement System grew its stake in shares of Haemonetics by 1.4% in the 1st quarter. Louisiana State Employees Retirement System now owns 14,100 shares of the medical instruments supplier's stock valued at $896,000 after purchasing an additional 200 shares during the period. CWC Advisors LLC. grew its stake in shares of Haemonetics by 7.4% in the 4th quarter. CWC Advisors LLC. now owns 3,083 shares of the medical instruments supplier's stock valued at $241,000 after purchasing an additional 212 shares during the period. Vise Technologies Inc. grew its stake in shares of Haemonetics by 8.7% in the 4th quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier's stock valued at $221,000 after purchasing an additional 225 shares during the period. TD Waterhouse Canada Inc. bought a new stake in shares of Haemonetics in the 4th quarter valued at approximately $25,000. Finally, KBC Group NV grew its stake in shares of Haemonetics by 19.9% in the 1st quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier's stock valued at $154,000 after purchasing an additional 401 shares during the period. 99.67% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金最近也增加或减少了在该公司的持股。路易斯安那州员工退休系统在第一季度将其在海默尼克斯的股份增加了 1.4%。路易斯安那州员工退休系统现在持有 14,100 股医疗仪器供应商的股票，价值 896,000 美元，此前在此期间额外购买了 200 股。CWC Advisors LLC 在第四季度将其在海默尼克斯的股份增加了 7.4%。CWC Advisors LLC 现在持有 3,083 股医疗仪器供应商的股票，价值 241,000 美元，此前在此期间额外购买了 212 股。Vise Technologies Inc.在第四季度将其在海默尼克斯的股份增加了 8.7%。Vise Technologies Inc.现在持有 2,825 股医疗仪器供应商的股票，价值 221,000 美元，此前在此期间额外购买了 225 股。TD Waterhouse Canada Inc.在第四季度购买了海默尼克斯的新股份，价值约 25,000 美元。最后，KBC Group NV 在第一季度将其在海默尼克斯的股份增加了 19.9%。KBC Group NV 现在持有 2,417 股医疗仪器供应商的股票，价值 154,000 美元，此前在此期间额外购买了 401 股。目前 99.67% 的股票由机构投资者持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several research firms have recently weighed in on HAE. JPMorgan Chase &amp; Co. reiterated a &#34;neutral&#34; rating and issued a $62.00 price objective (down from $85.00) on shares of Haemonetics in a research note on Friday. JMP Securities reiterated a &#34;market outperform&#34; rating and issued a $100.00 price objective on shares of Haemonetics in a research note on Tuesday, May 20th. Wall Street Zen lowered Haemonetics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, May 13th. Needham &amp; Company LLC lowered their price objective on Haemonetics from $84.00 to $68.00 and set a &#34;buy&#34; rating on the stock in a research note on Thursday. Finally, Mizuho lowered their price objective on Haemonetics from $90.00 to $70.00 and set an &#34;outperform&#34; rating on the stock in a research note on Friday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $87.64.</p>
<div class="lb-trans"><p>几家研究公司最近对 HAE 发表了看法。摩根大通重申了对海默尼克斯的 “中性” 评级，并在周五的研究报告中将目标价下调至 62.00 美元（之前为 85.00 美元）。JMP 证券在 5 月 20 日的研究报告中重申了对海默尼克斯的 “市场表现优于大盘” 评级，并将目标价设定为 100.00 美元。Wall Street Zen 在 5 月 13 日的研究报告中将海默尼克斯的评级从 “买入” 下调至 “持有”。Needham &amp; Company LLC 在周四将海默尼克斯的目标价从 84.00 美元下调至 68.00 美元，并对该股票设定了 “买入” 评级。最后，瑞穗证券在周五将海默尼克斯的目标价从 90.00 美元下调至 70.00 美元，并对该股票设定了 “优于大盘” 评级。一位股票研究分析师对该股票给予了卖出评级，两位给予了持有评级，八位给予了买入评级，两位给予了强烈买入评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，共识目标价为 87.64 美元。</p>
</div><p><strong>Check Out Our Latest Report on Haemonetics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于海默尼克斯的最新报告</strong></p>
</div><h2>Haemonetics Price Performance</h2>
<div class="lb-trans"><h2>海默尼克斯价格表现</h2>
</div><p>Haemonetics stock opened at $53.88 on Friday. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.99 and a current ratio of 1.72. The firm has a market cap of $2.59 billion, a P/E ratio of 16.48, a P/E/G ratio of 0.90 and a beta of 0.40. The business's fifty day moving average is $72.88 and its two-hundred day moving average is $67.44. Haemonetics Corporation has a 52 week low of $53.25 and a 52 week high of $94.99.</p>
<div class="lb-trans"><p>海默尼克斯的股票在周五开盘价为 53.88 美元。该公司的债务与股本比率为 1.04，速动比率为 0.99，流动比率为 1.72。该公司的市值为 25.9 亿美元，市盈率为 16.48，市盈增长比率为 0.90，贝塔值为 0.40。该公司的 50 日移动平均线为 72.88 美元，200 日移动平均线为 67.44 美元。海默尼克斯公司的 52 周低点为 53.25 美元，52 周高点为 94.99 美元。</p>
</div><p>Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.10 EPS for the quarter, topping analysts' consensus estimates of $1.01 by $0.09. The company had revenue of $321.39 million for the quarter, compared to analyst estimates of $305.12 million. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%. The business's revenue was down 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.02 earnings per share. Equities research analysts forecast that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>海默尼克斯（纽约证券交易所代码：HAE - 获取免费报告）最近在 8 月 7 日发布了季度财报。该医疗仪器供应商报告季度每股收益为 1.10 美元，超出分析师一致预期的 1.01 美元，超出幅度为 0.09 美元。该公司季度收入为 3.2139 亿美元，而分析师预期为 3.0512 亿美元。海默尼克斯的股本回报率为 26.64%，净利润率为 12.14%。该公司的收入同比下降了 4.4%。在去年同期，该公司每股收益为 1.02 美元。股票研究分析师预测海默尼克斯公司本财年的每股收益将达到 4.55 美元。</p>
</div><h2>Haemonetics Profile</h2>
<div class="lb-trans"><h2>海默尼克斯简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.</p>
<div class="lb-trans"><p>海默尼克斯公司是一家医疗保健公司，在美国和国际上提供一系列医疗产品和解决方案。该公司提供自动化血浆采集系统、捐赠者管理软件及支持软件解决方案，包括 NexSys PCS 和 PCS2 血浆分离设备及相关耗材和解决方案，以及集成的信息技术平台，供血浆客户管理其捐赠者、运营和供应链；以及 NexLynk DMS 捐赠者管理系统和 Donor360 应用程序。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Haemonetics</li>
<li>Want to Profit on the Downtrend? Downtrends, Explained.</li>
<li>MarketBeat Week in Review – 08/04 - 08/08</li>
<li>Stock Average Calculator</li>
<li>Airbnb Beats Earnings, But the Growth Story Is Losing Altitude</li>
<li>What is a Death Cross in Stocks?</li>
<li>Netflix Bulls vs. Bears: Who Wins This Pullback?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好五只股票，而不是海默尼克斯</li>
<li>想在下跌趋势中获利？下跌趋势解析。</li>
<li>MarketBeat 周回顾 – 08/04 - 08/08</li>
<li>股票平均计算器</li>
<li>Airbnb 超出收益预期，但增长故事正在失去高度</li>
<li>股票中的死亡交叉是什么？</li>
<li>Netflix 的多头与空头：谁将在这次回调中获胜？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=HAE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Haemonetics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在海默尼克斯吗？</h2>
</div><p>Before you consider Haemonetics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑海默尼克斯之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Haemonetics 并不在名单上。</p>
</div><p>While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Haemonetics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Global Alpha Capital Management Ltd. 购入了海蒙尼蒂克公司（NYSE: HAE）10,452 股股票